Trials / Completed
CompletedNCT03639090
Mass Spectrometry in Single Bladder Cancer Cells
Mass Spectrometry Detection of Drugs in Single Bladder Cancer Cells From Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2 (actual)
- Sponsor
- University of Oklahoma · Academic / Other
- Sex
- All
- Age
- 30 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The study is a pilot study in the feasibility of a diagnostic technique. There is no current data on detection of cisplatin in cancer cells derived from human urine. This study will generate preliminary data so that future studies may be done with more definitive end points in mind.
Detailed description
The aim of this study is to determine the feasibility of using a novel mass spectrometry instrument to measure the intracellular concentration of chemotherapeutic drug within an active tumor cell. If successful, this technique could be applied to dosage streamlining in patients and customization of dosage based on individual tumor characteristics. It also opens the door to research on novel chemotherapy agents or agents not typically used in a specific malignancy to determine if therapeutic levels can be obtained in tumor cells. Personalized chemotherapy is an evolving field with the underlying goal being minimization of side effects of treatment while maximizing net patient benefit for therapy. A key difficulty in personalized chemotherapy is that the determination of therapeutic benefit comes well after the administration of treatment has been completed. For most forms of chemotherapy there does not exist a laboratory study that can determine the concentration of therapeutic agent within the tumor itself and as such, real time dose adjustments are based only on toxicity, not on tumor penetrance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | mass spectrometry | mass spectrometry for bladder cancer cells |
Timeline
- Start date
- 2017-07-01
- Primary completion
- 2020-10-08
- Completion
- 2020-10-08
- First posted
- 2018-08-20
- Last updated
- 2020-10-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03639090. Inclusion in this directory is not an endorsement.